More large trials needed to decide best duration of treatment with tamoxifenBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7171.1524 (Published 28 November 1998) Cite this as: BMJ 1998;317:1524
- D A Cameron, Senior lecturer in medical oncology
- Department of Oncology, Western General Hospital, Edinburgh EH4 2XU
EDITOR—I agree with Rea et al that we do not know the optimum duration of adjuvant tamoxifen treatment.1 The data that they presented, however, suggest that the trials they advocated—ATLAS (adjuvant tamoxifen longer against shorter) and aTTom (adjuvant tamoxifen treatment offers more?)—may still fail to resolve this issue. The most recent overview, which provides much indirect evidence, suggests that five years is better than two, but it also reports a non-significant trend for the incidence of endometrial cancer to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial